Daniel Przybysz M.D.

In MD Anderson, we have treated all SBRT consecutive days including 54 Gy in 3 FX, 50 Gy (SIB GTV 60 Gy) in 4 Fx, 50 Gy (SIB GTV 60 Gy) in 5 Fx. We don’t observe any particular concerns for side effects and it is much convenient for our patients.

A Canadian study demonstrates that lung SBRT yields a similar success and safety profile when delivered on sequential versus every other day. Why? It’s likely because the rate of adverse events is minuscule in the first place. 🇨🇦 #Miniscule #radonc practicalradonc.org/article/S1879-…

After #ASCOGU26 and some deadlines approaching… we are OFF! ✈️ Our team has started all abstracts submissions for #2026. Let’s go! 🔥 #RadioSerra

5-20 brain mets, SRS improved quality of life as compared with HA-WBRT.

Another hit! 🎯 🫁 thanks @IASLC for this opportunity. Glad to contribute. #JTO #LungCancer #RadioSerra

Full hearted ❤️to have accomplished this. Helping our patients is the utmost goal in ☢️ medicine. #RadOnc brought me this. Thanks! Just finished our partnership with the #french + Haiti 🇭🇹 and @ATDQM on bringing updated tech and 1st world RT across boundaries. 🌎 #RadioSerra

2026 has started! 🎉 Very important to see this published, thanks @AUA for relying on us. ☢️ What a job by our team; leaded by MS4 Nicole Arbex. See you in #DC soon. 🇺🇸 #AUA #RadioSerra #AUA2026

Magnitude of benefit of SABR for EGFR+ disease is very similar to other treatments that are much more toxic @Mat_Guc

📌 Impact of whole‑brain radiation therapy on neurocognitive functions, alopecia and hearing loss: a systematic review and meta‑analysis endorsed by the Palliative Care and Neuro‑Oncology Study Groups of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) 🔗 pubmed.ncbi.nlm.nih.gov/41206407/ @OncoAlert #OncoAlertAF #RadOnc @AIRO80327989 🧠 the role of WBRT on neurocognitive functions, hearing, and alopecia, through the use of hippocampal-, scalp-, and cochlea-sparing radiotherapy (RT)

Back to what I think is a wrap up for the season: 🌎 thanks @AstraZeneca for keeping our MDTs always on the run. 🫁 #RadioSerra

Thanks for including me in this project Cinthya Sternberg 📕; honored to be part of it. 🫁 #GBOT

One of the greatest times of the year: the annual @GBOT_Alerta meeting. 🫁 🫁 🫁 See y’all in 2026 #GBOT #GBOT25

We’ve kicked off the #2026 season! #ASCOGU26 Congrats to our team; special efforts by Nicole Arbex #RadioSerra

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year results: • LRR 10.8% (TNT) vs 5.8% (CRT) → HR 1.91 • Spike seen only after sphincter-preserving surgery (SPS)  → 12.1% (TNT) vs 4.8% (CRT) (HR 2.6) • 🚨 If distal margin ≤ 10 mm → 25.4% (TNT) vs 1.8% (CRT) 💥 (HR 15.5) 🔍 Why? TNT causes tumour shrinkage but leaves scattered viable cells in the original tumour bed. ✂️ Cutting “too close” (<1 cm) may slice through microscopic disease → higher local recurrence. 🇸🇪🇳🇱 Geography tells the story: Sweden = more APR → no difference Netherlands = more SPS & tight margins → higher TNT LRR 🩻 Takeaway: TNT reduces distant mets ✅ but may raise local relapse if DRM ≤ 1 cm ⚠️ ➡️ Surgeons must factor in baseline tumour bed, not just post-TNT shrinkage. 📖 Prata I et al. Br J Surg 2025 🔗 doi.org/10.1093/bjs/zn… #OncoTwitter #ColorectalCancer #RectalCancer #RadOnc #Surgery @OncoAlert @esmo_open @BJSurgery @myESMO

We are proceeding with a similar approach to guide SABR versus surgery in early-stage lung ca, consolidative RT in stage IV ca. Cumulative , non-linear nature of interactions among risk factors are beyond the capacity of our brain. AI is the future in guiding personalized TX.

Is #AI 🤖 the future of ☢️ #RadOnc? #ASTRO25 pooled us: What innovation will most transform radiation oncology in the next 10 years? Cast your vote by dropping a ball; (Options in comments) Guess what??? #RadOnc #RadioSerra

That’s a wrap for 2025’s @ASTRO_org #ASTRO25; see you in Boston 🦞 #ASTRO26 #RadioSerra

🫁⚡ SABR in ILD — can planning make it safer? ASPIRE-ILD (secondary dosimetric analysis) in early-stage NSCLC + ILD (n=39) treated 50 Gy/5 fx (QOD) 🧩 Trial essentials • Design: single-arm SABR; dosimetry ↔ outcomes • Regimen: 50 Gy / 5 fx, every other day 🎯 What predicted toxicity/control? ❤️ Higher heart dose (Dmax, D15cc) → ↑ grade ≥2 AEs 🧱 Denser peritumoral lung (HU within 2 cm of PTV) → ↑ toxicity 📦 Bigger iGTV/PTV → ↓ LC & ↓ OS • 🫁 Worse OS with CTD-ILD/IPF subtype, prior ILD meds, home O₂, lower DLCO • 🚭 Smoking cessation → ↑ 6-mo FACT-L (QoL) 📊 Parent trial outcomes: 2-yr LC 92%, median OS 25 mo; grade 5 = 7.7% (respiratory) 💡 Takeaway: Keep ❤️ dose ultra-low, avoid shooting through dense fibrosis, be extra cautious with large targets, and push smoking cessation. 🔖 Save for tumor boards 📖 Dang A, Palma DA, Wang E, et al. Int J Radiat Oncol Biol Phys. 2025. 🔗doi.org/10.1016/j.ijro… #RadOnc #LCSM #NSCLC #ILD #SBRT #MedTwitter #OncoTwitter @OncoAlert @astro

I has become a tradition! “Autograph-like” picture w/ this 🤳 amazing friend and superstar @_ShankarSiva 🇦🇺; CONGRATS 🍾 on this amazing project - thanks for 🍺 and see you soon! 🔜 ✈️ #IROCK #ASTRO25 #PETERMAC